Recommendations of the German Society for Rheumatology on the perioperative approach under therapy with DMARDs and biologicals in inflammatory rheumatic diseases;Empfehlungen der Deutschen Gesellschaft für Rheumatologie zur perioperativen vorgehensweise unter therapie mit DMARD und biologicals bei entzündlich-rheumatischen erkrankungen

Zeitschrift fur Rheumatologie

Volumn 73, Issue 1, 2014, Pages 77-84

  Kruger K ^a   Albrecht, K ^a   Rehart, S ^a   Scholz, R ^a  

^a Praxiszentrum Sankt Bonifatius   (Germany)

Author keywords

Antirheumatic agents; Arthroplasty; Consensus; Infection; Wound healing

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; LEFLUNOMIDE; METHOTREXATE;

ARTICLE; DRUG HALF LIFE; HUMAN; MEDICAL SOCIETY; PERIOPERATIVE PERIOD; RHEUMATIC DISEASE; RHEUMATOLOGY; RISK ASSESSMENT; WOUND HEALING;

ANTIRHEUMATIC AGENTS; HUMANS; PERIOPERATIVE CARE; PRACTICE GUIDELINES AS TOPIC; RHEUMATIC DISEASES; RHEUMATOLOGY; SURGICAL WOUND INFECTION;

EID: 84896712266     PISSN: 03401855     EISSN: 14351250     Source Type: Journal    
DOI: 10.1007/s00393-013-1301-z     Document Type: Article

References (52)

1. Pieringer H, Stuby U, Biesenbach G (2007) Patients with rheumatoid arthritis undergoing surgery: how should we deal with antirheumatic treat ment? Semin Arthritis Rheum 36:278-286 (Pubitemid 46517632)
2. Widmer AF (2001) New developments in diagnosis and treatment of infection in orthopedic implants. Clin Infect Dis 33(Suppl 2):S94-S106
3. Ruyssen-Witrand A, Gossec L, Salliot C et al (2007) Complication rates of 127 surgical procedures performed in rheumatic patients receiving tumor necrosis factor alpha blockers. Clin Exp Rheumatol 25:430-436 (Pubitemid 47091020)
4. Den Broeder AA, Creemers MC, Fransen J et al (2007) Risk factors for surgical site infections and other complications in elective surgery in patients with rheumatoid arthritis with special attention for anti-tumor necrosis factor: a large retrospective study. J Rheumatol 34:689-695 (Pubitemid 46641372)
5. Bongartz T, Halligan CS, Osmon DR et al (2008) Incidence and risk factors of prosthetic joint infection after total hip or knee replacement in patients with rheumatoid arthritis. Arthritis Rheum 59:1713-1720
6. Doran MF, Crowson CS, Pond GR et al (2002) Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 46:2287-2293
7. Listing J, Gerhold K, Zink A (2013) The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment. Rheumatology 52:53-61
8. Jain A, Witbreuk M, Ball C, Nanchahal J (2002) Influence of steroids and methotrexate on wound complications after elective rheumatoid hand and wrist surgery. J Hand Surg Am 27:449-455 (Pubitemid 34522572)
9. Galloway JB, Hyrich KL, Mercer LK et al (2011) Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheu matology Biologics Register with special emphasis on risks in the elderly. Rheumatology 50:124-131
10. Wolfe F, Caplan L, Michaud K (2006) Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. Arthritis Rheum 54:628-634 (Pubitemid 43228641)
11. Strangfeld A, Eveslage M, Schneider M et al (2011) Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient? Ann Rheum Dis 70:1914-1920
12. Dixon WG, Kezouh A, Bernatsky S, Suissa S (2011) The influence of systemic glucocorticoid therapy upon the risk of non-serious infection in older patients with rheumatoid arthritis: a nested case-control study. Ann Rheum Dis 70:956-960
13. Härle P, Straub RH, Fleck M (2010) Perioperative management of immunosuppression in rheumatic diseases-what to do? Rheumatol Int 30:999-1004
14. Scanzello CR, Figgie MP, Nestor BJ, Goodman SM (2006) Perioperative management of medications used in the treatment of rheumatoid arthritis. HSS J 2:141-147 (Pubitemid 44328110)
15. Bibbo C, Anderson RB, Davis WH, Norton J (2003) The influence of rheumatoid chemotherapy, age, and presence of rheumatoid nodules on postoperative complications in rheumatoid foot and ankle surgery: analysis of 725 procedures in 104 patients (corrected). Foot Ankle Int 24:40-44
16. Dvivedi S, Tiwari SM, Sharma A (1997) Effect of ibuprofen and diclofenac sodium on experimental would healing. Indian J Exp Biol 35:1243-1245 (Pubitemid 28011611)
17. Visser K, Katchamart W, Loza E et al (2009) Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann Rheum Dis 68:1086-1093
18. Bombardier C, Hazlewood GS, Akhavan P et al (2012) Canadian Rheumatology Association recommendations for the pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs: part II safety. J Rheumatol 39:1583-1602
19. Luqmani R, Hennell S, Estrach C et al (2009) British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of rheumatoid arthritis (after the first 2 years). Rheumatology (Oxford) 48:436-439
20. Ledingham J, Deighton C, British Society for Rheumatology Standards, Guidelines and Audit Working Group (2005) Update on the British Society for Rheumatology guidelines for prescribing TNFalpha blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001). Rheumatology (Oxford) 44:157-163 (Pubitemid 40277395)
21. Koike R, Takeuchi T, Eguchi K et al (2007) Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis. Mod Rheumatol 17:451-458
22. Saag KG, Teng GG, Patkar NM et al (2008) American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 59:762-784 (Pubitemid 351847559)
23. OCEBM Levels of Evidence Working Group*. "The Oxford 2011 Levels of Evidence". Oxford Centre for Evidence-Based Medicine. http://www.cebm.net/ index.aspx?o=5653
24. Loza E, Martinez-Lopez JA, Carmona L (2009) A systematic review on the optimum management of the use of methotrexate in rheumatoid arthritis patients in the perioperative period to minimize perioperative morbidity and maintain disease control. Clin Exp Rheumatol 27:856-862
25. Grennan DM, Gray J, Loudon J, Fear S (2001) Methotrexate and early postoperative complications in patients with rheumatoid arthritis undergoing elective orthopaedic surgery. Ann Rheum Dis 60:214-217 (Pubitemid 32260601)
26. Sany J, Anaya JM, Canovas F et al (1993) Influence of methotrexate on the frequency of postoperative infectious complications in patients with rheumatoid arthritis. J Rheumatol 20:1129-1132 (Pubitemid 23278162)
27. Sreekumar R, Gray J, Kay P, Grennan DM (2011) Methotrexate and postoperative complications in patients with rheumatoid arthritis undergoing elective orthopaedic surgery-a ten year follow-up. Acta Orthop Belg 77:823-826
28. Murata K, Yasuda T, Ito H et al (2006) Lack of increase in postoperative complications with low-dose methotrexate therapy in patients with rheumatoid arthritis undergoing elective orthopedic surgery. Mod Rheumatol 16:14-19
29. Perhala RS, Wilke WS, Clough JD, Segal AM (1991) Local infectious complications following large joint replacement in rheumatoid arthritis patients treated with methotrexate versus those not treated with methotrexate. Arthritis Rheum 34:146-152
30. Tanaka N, Sakahashi H, Sato E et al (2003) Examination of the risk of continuous leflunomide treatment on the incidence of infectious complications after joint arthroplasty in patients with rheumatoid arthritis. J Clin Rheumatol 9:115-118 (Pubitemid 36531884)
31. Fuerst M, Möhl H, Baumgärtel K, Rüther W (2006) Leflunomide increases the risk of early healing complications in patients with rheumatoid arthritis undergoing elective orthopedic surgery. Rheumatol Int 26:1138-1142 (Pubitemid 44450851)
32. Rehart S, Petak N (2007) Moderne rheumatische Basistherapie perioperativ. Akt Rheumatol 32:74-77
33. Van Riel PLCM, Smolen JS, Emery P et al (2004) Leflunomide: a manageable safety profile. J Rheumatol 31(Suppl 71):21-24 (Pubitemid 38703144)
34. Barnard AR, Regan M, Burke FD et al (2012) Wound healing with medications for rheumatoid arthritis in hand surgery. ISRN Rheumatol 2012:251962
35. Escalante A, Beardmore TD (1995) Risk factors for early wound complications after orthopedic surgery for rheumatoid arthritis. J Rheumatol 22:1844-1851
36. Cunha BM da, Maria Henrique da Mota L, Dos Santos-Neto LL (2012) Risk of orthopedic surgical site infections in patients with rheumatoid arthritis treated with antitumor necrosis factor alfa therapy. Int J Rheumatol 2012:369565
37. Goh L, Jewell T, Laversuch C, Samanta A (2012) Should anti-TNF therapy be discontinued in rheumatoid arthritis patients undergoing elective orthopaedic surgery? A systematic review of the evidence. Rheumatol Int 32:5-13
38. Pieringer H, Danninger K, Tzaribachev N et al (2013) Patients with arthritis undergoing surgery: how should we manage tumour necrosis factor blocking agents perioperatively?-A systematic literature review. Yonsei Med J 54:253-257
39. Giles JT, Bartlett SJ, Gelber AC et al (2006) Tumor necrosis factor inhibitor therapy and risk of serious postoperative orthopedic infection in rheumatoid arthritis. Arthritis Rheum 55:333-337
40. Kawakami K, Ikari K, Kawamura K et al (2010) Complications and features after joint surgery in rheumatoid arthritis patients treated with tumour necrosis factor-alpha blockers: perioperative interruption of tumour necrosis factor-alpha blockers decreases complications? Rheumatology (Oxford) 49:341-347
41. Bibbo C, Goldberg JW (2004) Infectious and healing complications after elective orthopaedic foot and ankle surgery during tumor necrosis factor-alpha inhibition therapy. Foot Ankle Int 25:331-335 (Pubitemid 39096154)
42. Kubota A, Nakamura T, Miyazaki Y et al (2012) Perioperative complications in elective surgery in patients with rheumatoid arthritis treated with biologics. Mod Rheumatol 22:844-848
43. Talwalkar SC, Grennan DM, Gray J et al (2005) Tumour necrosis factor alpha antagonists and early postoperative complications in patients with inflammatory joint disease undergoing elective orthopaedic surgery. Ann Rheum Dis 64:650-651 (Pubitemid 40469105)
44. Wendling D, Balblanc JC, Brousse A et al (2005) Surgery in patients receiving anti-tumour necrosis factor alpha treatment in rheumatoid arthritis: an observational study on 50 surgical procedures. Ann Rheum Dis 64:1378-1379 (Pubitemid 41206266)
45. Gilson M, Gossec L, Mariette X et al (2010) Risk factors for total joint arthroplasty infection in patients receiving tumor necrosis factor α-blockers: a case-control study. Arthritis Res Ther 12:R145
46. Pham T, Bachelez H, Berthelot JM et al (2011) TNF alpha antagonist therapy and safety monitoring. Joint Bone Spine 78(Suppl 1):15-185
47. Nishida K, Nasu Y, Hashizume K et al (2013) Abatacept management during the perioperative period in patients with rheumatoid arthritis: report on eight orthopaedic procedures. Mod Rheumatol (Epub ahead of print)
48. Pham T, Bachelez H, Berthelot JM et al (2012) Abatacept therapy and safety management. Joint Bone Spine 79(Suppl 1):3-84
49. Kaufmann D, Arbogast M (2010) Prä- und postoperatives Management von Patienten unter Rituximabtherapie. Akt Rheumatol 35:368-388
50. Momohara S, Hashimoto J, Tsuboi H et al (2012) Analysis of perioperative clinical features and complications after orthopaedic surgery in rheumatoid arthritis patients treated with tocilizumab in a real-world setting: results from the multicentre TOcilizumab in Perioperative Period (TOPP) study. Mod Rheumatol (Epub ahead of print)
51. Hirao M, Hashimoto J, Tsuboi H et al (2009) Laboratory and febrile features after joint surgery in patients with rheumatoid arthritis treated with tocilizumab. Ann Rheum Dis 68:654-657
52. Koike R, Harigai M, Atsumi T et al (2009) Japan College of Rheumatology 2009 guidelines for the use of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, in rheumatoid arthritis. Mod Rheumatol 19:351-357